



Ref: JSTL/BSE/BOD/2021-22/June21

Date: June 23, 2021

To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai - 400001.

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 23.06.2021

Ref: Regulation 30 and 33 along with Schedule III of SEBI (LODR) Regulations, 2015

With reference to the subject cited, this is to inform the Stock Exchange that at the Board Meeting of Jeevan Scientific Technology Limited held on Wednesday, 23.06.2021 at 11.30 A.M at the registered office of the company, approved the following items of business:

1. Audited Financial results (Standalone and Consolidated) together with Statement of Assets and Liabilities and Statement of Cash flow for the quarter and year ended 31.03.2021 (enclosed).
2. Auditors Report along with declaration of unmodified opinion for the year ended 31.03.2021(enclosed).
3. Dividend of 5% i.e., Rs. 0.50/- per share subject to approval of shareholders.
4. Granting of 9,00,000 options to the eligible employees of the company pursuant to JSTL ESOP Scheme 2016.
5. Appointment of Mrs. Snigdha Mothukuri as Chief Executive Officer of the Company (Brief profile is annexed as **Annexure - A**)
6. Appointment of Mr. Y. Nageswara Rao as Additional Director (Executive Category) of the company. (Brief profile is annexed as **Annexure - B**)
7. Appointment of M/s. K.P & Associates as Internal Auditors of the company for Financial Year 2021-22. (Brief Profile is annexed as **Annexure - C**)





8. Appointment of M/s. S.S. Reddy & Associates, Practicing Company Secretary, as a Secretarial Auditor of the Company for Financial Year 2021-22. (Brief Profile is annexed as **Annexure – D**)
9. Resignation of Mr. Rajendra Prasad Muppavarapu as Whole-time Director and Chief Executive Officer of the Company.

Note: Agenda items pertaining to the Annual General Meeting of the co., i.e., point no.s 3, 4, 6 and 7 of the intimation sent to Stock Exchange dated 14.06.2021 were deferred to the subsequent meeting, as mentioned below:

- To approve Notice, Directors report, Management Discussion and analysis and Corporate Governance Report for the year ended 31.03.2021.
- To convene the 22nd Annual General Meeting of the members of Company.
- To appoint scrutinizer for conducting e-voting in the ensuing Annual General Meeting.
- To approve Book closure for the purpose of Annual General Meeting.

Pursuant to SEBI Circular LIST/COMP/14/2018-19 dated June 20, 2018, it is hereby affirmed that **none** of the proposed appointments in point no.s' 5 and 6 above are debarred from holding the office of director by virtue of any order of SEBI or any other such authority.

The meeting concluded at 5.55 P.M.

This is for your Information and records.

Thanking You,

**For and on Behalf of the
Jeevan Scientific Technology Limited**


Krishna Kishore Kuchipudi
Vice Chairman and Managing Director
(DIN: 00876539)



**Annexure A**

Brief Profile of appointment/reappointment of directors of the company required as per Regulation 30 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Particulars	
Name of the Director	Snigdha Mothukuri
Designation	Executive Director and CEO
Date and term of appointment	Board appointed of Mrs. Snigdha Mothukuri as Chief Executive Officer of the company.
Brief Profile	<p>Ms. Snigdha Mothukuri is an enthusiastic honors graduate from the finest educational institutions across the globe. She pursued two master's degrees, one in the field of Management Science from a leading Ivy Leagues School - Columbia University in New York and the other in the field of Technology from the prestigious Indian Institute of Technology (IIT) Madras. She completed her Bachelor of Technology from IIT Madras.</p> <p>During her tenure with the company i.e. since 2018 onwards, she played a key role in the overall organizational growth including Strategy Deployment, Operations, Project Management and Finance which have significantly contributed to the financial performance of the company.</p> <p>Prior to Jeevan Scientific Technology Limited, she worked with reputed organizations like Lansum Estates LLP (India), Louis Vuitton (USA), Fresh Direct (USA), University of British Columbia (Canada) and Aarvee Associates (India).</p> <p>Having worked with global teams in highly distributed environments, she gained industry experience in domains ranging from Health Care, Pharma, Civil Engineering, Transportation, Supply Chain to Operations and Finance. While working at Lansum Estates, she was part of the Management team and handled the construction of the tallest residential towers in the State of Andhra Pradesh - Lansum Oxygen Towers.</p> <p>She has proved to be a technical and research person, an astute analyst as well as a team player and a team leader.</p>
Disclosure of relationships between directors	Daughter in law of Krishna Kishore Kuchipudi and wife of Jeevan Krishna Kuchipudi





Annexure B

Brief Profile of appointment/reappointment of directors of the company required as per Regulation 30 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Particulars	
Name of the Director	Y. Nageswara Rao
Designation	Executive Director
Date and term of appointment	<ul style="list-style-type: none">• Board has appointed Mr. Nageswara Rao as an Additional Director whose directorship is subject to regularization u/s. 161 of the Companies Act, 2013.• Board has appointed Mr. Nageswara Rao as an Executive Director whose directorship is subject to approval of the shareholders pursuant to the provisions of Companies Act, 2013.
Brief Profile	<p>Nageswara Rao is an experienced professional in the areas of Management, Operations, Finance Marketing and Administration. Currently a Director of Sri Surya Wheels Private Limited, he has an overall experience of over 30 years successfully managing multiple organisations – Sri Surya Automobiles, Sri Surya Transport Corporation, Sri Surya Wheels Private Limited, Sri Surya Electronics and Home Appliances.</p> <p>He has gained multiple awards in the field of marketing and has rich experience in managing multiple teams across various levels and locations.</p>
Disclosure of relationships between directors	None





Annexure - C

Brief Profile of M/s. K P & Associates (Internal Auditors)

K P & Associates was established in the year 2009 as Partnership concern with two partners. The firm currently having employee strength of 15 members in addition to 2 Chartered Accountants (FCA). The firm was established with the aim of providing value added professional services in various fields. They're experienced in the field of Statutory Audit, Internal Audit, Financial Consultancy, Advisory Services, Corporate Laws, Business Processing Outsourcing and Tax Management.

Annexure D

Brief Profile of M/s. S.S Reddy & Associates (Secretarial Auditors)

M/s. S.S. Reddy & Associates, established in the year 2007 by Mr. S. Sarveswar Reddy having a wide client base ranging from Listed and Unlisted Companies in Infra and Real Estate, Defence, Software, Pharma etc., to Government Companies. M/s S.S. Reddy & Associates is having more than 100 corporate clients. Till date they have handled numerous corporate actions such as Initial Public Offers (IPOs), Takeovers, preferential issues, bonus issues, rights issues, buyback, mergers and demergers, delisting, revocation of suspension, corporate restructuring and so on. It is well known firm for corporate advisory services pertaining to Company Law, SEBI Regulations, FEMA, Securities Laws etc.





Ref: JSTL/BSE/BOD/2021-22/June21

Date: June 23, 2021

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

Ref: Scrip Code - 538837

I, K. Krishna Kishore, Vice Chairman and Managing Director of Jeevan Scientific Technology Limited hereby declare that, the Statutory Auditors of the company, M/s. Pavuluri & Co have issued an Audit Report with unmodified/unqualified opinion on Standalone and Consolidated Audited Financial Results of the company for the quarter and year ended 31st March, 2021.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide. Circular No. No. CIR/CFD/CMD/56/2016 dated 27-05-2016.

Thanking you,

Yours faithfully,

For Jeevan Scientific Technology Limited


K. Krishna Kishore
Vice Chairman and Managing Director
(DIN: 00876539)





INDEPENDENT AUDITOR'S REPORT ON AUDIT OF STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Opinion

We have audited the accompanying Statement of Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** (the "Company"), for the three months and year ended March 31, 2021 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- b. gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net loss and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2021.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SA's") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Financial Results

This Statement, is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Interim condensed financial statements for the year ended March 31, 2021. The Company's Board of Directors are responsible for the preparation and presentation of the Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.



Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Results.

**PAVULURI & Co.****CHARTERED ACCOUNTANTS**

Plot No.48, Flat No.301,
Micasa, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : pavuluriandco@gmail.com

Materiality is the magnitude of misstatements in the Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Pavuluri & Co
Chartered Accountants
(FRN : 012194S)

**RAJESH
NUKAVARAPU**

Digitally signed by
RAJESH NUKAVARAPU
Date: 2021.06.23
15:05:01 +05'30'

CA N Rajesh
Partner

M.No : 223169

UDIN # 21223169AAAAEO7574

Date : 23/06/2021

Place : Hyderabad

Branches :

Flat No : 301, Block C, Green City Towers, Green City Township, Near Export Apparel Park, **Visakhapatnam** - 530049.
Flat No.: 504, Madhu Towers, Srinivasa Nagar Bank Colony, **Vijayawada** - 520008, Ph : 0866-2545418

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Gokonda Post, Hyderabad-500008,
STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND THE YEAR ENDED 31ST MARCH, 2021

Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			Year Ended	
		31-03-2021 Audited	31-12-2020 UnAudited	31-03-2020 Audited	31-03-2021 Audited	31-03-2020 Audited
1	Income					
	(a) Revenue From Operations	1355.89	1442.30	556.68	4139.36	2056.74
	(b) Other Income	7.85	23.34	65.32	92.43	156.30
	(c) Unbilled Revenue	0.00	0.00	95.80	53.00	95.80
	Total income	1,363.74	1,465.64	717.80	4,284.79	2,308.84
2	Expenses					
	(a) Cost of Material Consumed	117.14	87.49	39.16	274.55	156.89
	(b) Purchase of stock-in-trade		-	-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(33.70)	(89.00)	(70.40)	(210.30)	(70.40)
	(d) Employee benefit expense	275.42	246.94	206.5	917.72	820.86
	(e) Finance Cost	33.13	40.67	53.78	171.86	226.82
	(f) Depreciation and Amortisation expense	98.31	99.29	93.04	395.52	390.78
	(g) Other Expenses	526.98	357.64	283.2	1417.59	1021.67
	Total Expenses	1,017.28	743.03	605.28	2,966.94	2,546.62
3	Profit before exceptional items and Tax	346.46	722.61	112.52	1,317.85	-237.78
4	Add(+)/Less(-) Exceptional items	-	-	739.24	-	739.24
5	Profit/ (Loss) before Tax	346.46	722.61	-626.72	1,317.85	-977.02
6	Tax Expenses	-0.24	121.97	126.56	191.92	195.55
7	Profit(Loss) for the Period from Continuing Operations	346.70	600.64	-500.16	1,125.93	-781.47
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-
9	Tax Expenses on discontinuing Operations	-	-	-	-	-

Sl.No	Particulars	Quarter Ended				Year Ended	
		31-03-2021 Audited	31-12-2020 UnAudited	31-03-2020 Audited	31-03-2021 Audited	31-03-2020 Audited	31-03-2020 Audited
10	Profit(Loss) from Discontinuing Operations after Tax	-	-	-	-	-	-
11	Profit(Loss) for the period	346.70	600.64	-500.16	1,125.93	-781.47	-
12	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	6.8	-0.28	4.34	5.96	-2.43	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period	353.50	600.36	-495.82	1,131.89	-783.90	-
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	-
15	Other equity excluding revaluation reserve	-	-	-	2094.74	962.83	-
16	Earnings per Equity share (for continuing operations)						
	a) Basic (Amount in Rupees)	2.31	3.92	-3.24	7.40	-5.12	-
	b) Diluted (Amount in Rupees)	2.31	3.92	-3.24	7.40	-5.12	-
17	Earnings per Equity share (for discontinued operations)						
	a) Basic (Amount in Rupees)	-	-	-	-	-	-
	b) Diluted (Amount in Rupees)	-	-	-	-	-	-
18	Earnings per Equity share (for Continuing & discontinued operations)						
	a) Basic (Amount in Rupees)	2.31	3.92	-3.24	7.40	-5.12	-
	b) Diluted (Amount in Rupees)	2.31	3.92	-3.24	7.40	-5.12	-

Notes to the Standalone Audited Financial Results

- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The above results have been reviewed by the Audit Committee at its meeting held on 23.06.2021 and approved by the Board of Directors of the Company on the same date.
- During the year, Company is operating in only one segment i.e., Clinical Research Services
- The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of the above assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The company will continue to monitor any material changes in future economic conditions.
- Figures for the previous periods have been rearranged wherever necessary.

for Jeevan Scientific Technology Limited

On behalf of the Board of Directors

K. Krishna Kishore
Vice Chairman & Managing Director

M. Srikanth Sasidhar
CFO

Place: Hyderabad
Date: 23.06.2021



Jeewan Scientific Technology Limited
Stand alone Balance Sheet as at 31st Mar, 2021

Particulars	(In Rupees)	
	As at 31.03.2021	As at 31.03.2020
Assets		
(1) Non-current Assets		
a) Property, Plant and Equipment	158,688,106	177,299,661
b) Other Intangible Assets	4,938,787	7,190,030
c) Intangible Assets Process Knowhow	41,642,037	52,361,147
d) Financial Assets		
i) Investments	10,269,070	10,269,070
ii) Loans	65,286,870	62,146,546
iii) Advances	41,300,902	36,909,796
c) Deferred tax asset (net)	6,061,921	15,738,838
(2) Current Assets		
a) Inventories	34,557,046	9,467,418
b) Financial Assets		
i) Trade receivables	124,584,286	60,011,297
ii) Cash and cash equivalents	27,284,585	18,259,938
iii) Bank balances other than (i) above	29,563,173	563,173
iv) Loans & Advances (current)	5,110,498	7,087,171
v) Other Financial Assets	22,997,445	18,326,222
c) Current Tax Assets (Net)	45,952,303	41,485,587
d) Other Current Assets	19,509,389	11,636,078
Total	637,766,418	528,751,971
Equity and Liabilities		
Equity		
a) Equity Share Capital	153,014,650	153,014,650
b) Other Equity	209,473,657	96,282,842
Liabilities		
(1) Non-current Liabilities		
a) Financial liabilities		
Borrowings	77,699,329	79,027,246
b) Provisions	3,199,910	2,558,949
c) Deferred tax Liability (net)	-	-
(2) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	506,177	73,650,912
ii) Trade Payables	26,358,431	24,573,412
iii) Other Financial liabilities	31,954,508	38,958,654
iv) Other Financial Creditors	7,042,253	20,857,086
b) Other current liabilities	111,159,011	36,675,179
c) Provisions	17,358,492	3,153,041
Total	637,766,418	528,751,971

Place: Hyderabad
Date: 23.06.2021

for Jeewan Scientific Technology Limited
On behalf of the Board of Directors


K. Krishna Kishore
Vice Chairman & Managing Director

M Srikanth Sasidhar
CFO



Jeevan Scientific Technology Limited			
Stand alone Cash flow statement for the Year ended 31st Mar, 2021			
		(In Rupees)	
S.No	Particulars	As at 31.03.2021	As at 31.03.2020
A.	Cash flow from operating activities		
	Net Profit before tax and extraordinary items	131,786,490	(97,702,147)
	Adjustments for:		
	Depreciation	39,551,686	39,078,307
	Other Comprehensive Income	596,107	(242,512)
	Loss on Sale of Assets	-	306,407
	Interest	17,185,601	22,680,631
	Operating profit before working capital changes	189,119,884	(35,879,314)
	Changes in Working Capital		
	Inventories	(25,089,628)	(7,163,379)
	Trade and other receivables	(87,138,996)	55,358,815
	Trade and other Payables	(6,828,467)	21,139,122
	Cash generated from operations before Tax	83,719,726	(8,823,000)
	Tax Provision	19,191,782	(19,554,556)
	Provision for Dividend	-	-
	Interest paid	17,185,601	22,680,631
	Net cash from operating activity	47,342,343	(11,949,075)
B.	Cash flow from investing activities		
	Purchase of fixed assets	(7,989,778)	(11,009,324)
	Investments	-	-
	Sale / Transfer of fixed assets	-	850,676
	Net cash used in investing activity	(7,989,778)	(10,158,648)
C.	Cash flow from financing activity		
	Proceeds from loans	(1,327,917)	4,372,256
	Increase in Capital	-	-
	Increase in Other Equity	-	-
	Net cash generated in financing activity	(1,327,917)	4,372,256
	Net increase in cash and cash equivalents (A+B+C)	38,024,648	(17,735,467)
	Cash and cash equivalents as at 31.03.2020	18,823,112	36,558,579
	Cash and cash equivalents as at 31.03.2021	56,847,760	18,823,112

Place: Hyderabad
Date: 23.06.2021

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors

K. Krishna Kishore
Vice Chairman & Managing Director


M. Srikanth Sasidhar
CFO





INDEPENDENT AUDITOR'S REPORT ON AUDIT OF CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** (the "Company"), and its subsidiary (the Company and the subsidiary together referred to as "the Group") for the three months and year ended March 31, 2021 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net loss and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2021.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Financial Results

This Statement, is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Interim condensed consolidated financial statements for the year ended March 31, 2021. The Company's Board of Directors are responsible for the preparation and presentation of the Consolidated Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Consolidated Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease



operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

**PAVULURI & Co.**

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,
Micasa, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : pavuluriandco@gmail.com

- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Results.

Materiality is the magnitude of misstatements in the Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Pavuluri & Co
Chartered Accountants
(FRN : 012194S)

RAJESH
NUKAVARAPU

Digitally signed by
RAJESH NUKAVARAPU
Date: 2021.06.23
15:03:57 +05'30'

CA N Rajesh
Partner
M.No : 223169
UDIN # 21223169AAAAEP9264

Date : 23/06/2021

Place : Hyderabad

Branches :

Flat No : 301, Block C, Green City Towers, Green City Township, Near Export Apparel Park, **Visakhapatnam** - 530049.
Flat No.: 504, Madhu Towers, Srinivasa Nagar Bank Colony, **Vijayawada** - 520008, Ph : 0866-2545418

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office/Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagit, Near Lanco Hills, Hyderabad-500008.
CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2021

Rupees in Lakhs


Sl.No	Particulars	Quarter Ended			Year Ended	
		31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020
		Audited	UnAudited	Audited	Audited	Audited
1	Income					
	(a) Revenue From Operations	1537.28	1578.73	707.69	4787.59	2394.09
	(b) Other Income	9.13	23.34	65.51	93.91	157.60
	(c) Unbilled Revenue	0.00	0.00	95.80	53.00	95.80
	Total income	1,546.41	1,602.07	869.00	4,934.50	2,647.49
2	Expenses					
	(a) Cost of Material Consumed	117.14	87.49	39.16	274.55	156.89
	(b) Purchase of stock-in-trade	-	-	-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-33.70	-89.00	(70.40)	-210.30	-70.40
	(d) Employee benefit expense	360.33	328.24	293.74	1253.34	1044.52
	(e) Finance Cost	15.24	58.59	71.67	209.36	273.13
	(f) Depreciation and Amortisation expense	98.63	99.62	93.36	396.83	392.05
	(g) Other Expenses	605.76	422.17	378.71	1645.78	1166.37
	Total Expenses	1,163.40	907.11	806.24	3,569.56	2,962.56
3	Profit before exceptional items and Tax	383.01	694.96	62.76	1,364.94	-315.07
4	Add(+) / Less(-) Exceptional items	-	-	739.24	0.00	739.24
5	Profit/ (Loss) before Tax	383.01	694.96	-676.48	1,364.94	-1,054.31
6	Tax Expenses	-1.22	121.97	126.72	190.94	195.71
7	Profit(Loss) for the Period from Continuing Operations	384.23	572.99	-549.76	1174.00	-858.60
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-
9	Tax Expenses on discontinuing Operations	-	-	-	-	-

Sl.No	Particulars	Quarter Ended				Year Ended	
		31-03-2021 Audited	31-12-2020 UnAudited	31-03-2020 Audited	31-03-2021 Audited	31-03-2020 Audited	31-03-2020 Audited
10	Profit(Loss) from Discontinuing Operations after Tax	-	-	-	-	-	-
11	Profit(Loss) for the period	384.23	572.99	-549.76	1,174.00	-858.60	
12	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	6.8	-0.28	4.34	5.96	-2.43	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	
13	Total Comprehensive Income for the period	391.03	572.71	-545.42	1,179.96	-861.03	
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	
15	Other equity excluding revaluation reserve				1972.12	792.14	
16	Earnings per Equity share (for continuing operations)						
	a) Basic (Amount in Rupees)	2.56	3.74	-3.56	7.71	-5.63	
	b) Diluted (Amount in Rupees)	2.56	3.74	-3.56	7.71	-5.63	
17	Earnings per Equity share (for discontinued operations)						
	a) Basic (Amount in Rupees)						
	b) Diluted (Amount in Rupees)						
18	Earnings per Equity share (for Continuing & discontinued operations)						
	a) Basic (Amount in Rupees)	2.56	3.74	-3.56	7.71	-5.63	
	b) Diluted (Amount in Rupees)	2.56	3.74	-3.56	7.71	-5.63	

Notes to the Consolidated Audited Financial Results

- 1 The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- 2 The above results have been reviewed by the Audit Committee at its meeting held on 23.06.2021 and approved by the Board of Directors of the Company on the same date.
- 3 The Group currently has two segments (i) clinical research services and (ii) Information technology services.
- 4 The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of the above assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The company will continue to monitor any material
- 5 Figures for the previous periods have been rearranged wherever necessary.
- 6 The above consolidated financial results include the Audited financial results of the wholly owned subsidiaries, M/s Enhops Solutions Pvt Ltd & Enhops Inc.

Place: Hyderabad
Date: 23.06.2021

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors

K. Krishna Kishore
Vice Chairman & Managing Director


M. Srikanth Sasidhar
CFO



SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED (Consolidated Unaudited)
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2021

Particulars	Quarter Ended			Year Ended	
	31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020
	Audited	Unaudited	Audited	Audited	Audited
SEGMENT REVENUE: (Net Sales / Income from Operations)					
a) Clinical Research Services	1,363.74	1,465.64	717.8	4,284.79	2,308.84
b) Information Technology Services	182.67	136.43	151.20	649.71	338.65
Total:	1,546.41	1,602.07	869.00	4,934.50	2,647.49
LESS: Inter Segment revenue	-	-	-	-	-
Net Sales / Income from Operations.	1,546.41	1,602.07	869.00	4,934.50	2,647.49
SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST					
a) Clinical Research Services	361.47	763.28	166.30	1,489.47	-10.96
b) Information Technology Services	36.78	(9.73)	-31.87	84.83	-30.98
Total:	398.25	753.55	134.43	1,574.30	-41.94
LESS:					
i) Interest	15.24	58.59	71.67	209.36	273.13
ii) Other Un-Allocable Expenditure	-	-	-	-	-
iii) Un-Allocable Income	-	-	-	-	-
TOTAL PROFIT /(-LOSS) BEFORE TAX	383.01	694.96	62.76	1,364.94	-315.07

Place: Hyderabad
Date: 23.06.2021

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors
[Signature]
K. Krishna Kishore
Vice Chairman & Managing Director

[Signature]
M Srikanth Sasidhar
CFO



Jeevan Scientific Technology Limited
Consolidated Balance Sheet as at 31st Mar. 2021

Particulars	(In Rupees)	
	As at 31.03.2021	As at 31.03.2020
Assets		
(1)Non-current Assets		
a) Property, Plant and Equipment	158,801,128	177,437,573
b) Other Intangible Assets	5,035,963	7,373,434
c) Intangible Assets Process Knowhow	109,912,943	120,632,053
d) Financial Assets		
i) Investments		-
ii) Loans		
iii) Advances	41,300,902	36,909,796
c) Deferred tax asset (net)	6,030,046	13,608,907
(2)Current Assets		
a) Inventories	34,557,046	9,467,418
b) Financial Assets		
i) Trade receivables	144,454,440	68,432,795
ii) Cash and cash equivalents	32,551,931	21,398,972
iii) Bank balances other than (i) above	29,563,173	563,173
iv) Loans	5,191,862	7,087,171
v) Other Financial Assets	22,997,445	18,326,222
c) Current Tax Assets (Net)	49,694,322	43,886,278
d) Other Current Assets	19,686,073	11,636,078
Total	659,777,274	538,759,869
Equity and Liabilities		
Equity		
a) Equity Share Capital	153,014,650	153,014,650
b) Other Equity	197,212,727	79,214,498
Liabilities		
(1)Non-current Liabilities		
a) Financial liabilities		
Borrowings	77,699,329	79,027,246
b) Provisions	3,199,910	2,558,949
c) Deferred tax Liability (net)	-	
(2)Current Liabilities		
a) Financial Liabilities		
i) Borrowings	506,177	73,650,912
ii) Trade Payables	32,596,752	24,573,412
iii) Other Financial liabilities	54,951,953	57,284,876
iv) Other Financial Creditors	7,042,253	20,857,086
b) Other current liabilities	116,195,032	45,425,199
c) Provisions	17,358,491	3,153,041
Total	659,777,274	538,759,869

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors

Place:Hyderabad
Date:23.06.2021

K. Krishna Kishore
Vice Chairman & Managing Director

M Srikanth Sasidhar
CFO



Jeevan Scientific Technology Limited			
Consolidated Cash Flow statement for the year ended 31st Mar, 2021			
S.No	Particulars	(In Rupees)	
		As at 31.03.2021	As at 31.03.2020
A.	Cash flow from operating activities		
	Net Profit before tax and extraordinary items	136,495,847	(105,430,532)
	Adjustments for:		
	Depreciation	39,682,804	39,205,126
	Other Comprehensive Income	596,107	(242,512)
	Loss on Sale of Assets	-	306,407
	Interest	20,935,849	27,312,291
	Operating profit before working capital changes	197,710,607	(38,849,220)
	Changes in Working Capital		
	Inventories	(25,089,628)	(7,163,379)
	Trade and other receivables	(97,046,707)	61,790,468
	Trade and other Payables	(13,925,959)	8,129,975
	Cash generated from operations before Tax	89,500,231	7,647,895
	Taxes Provision	19,093,726	(19,570,433)
	Provision for Dividend	-	-
	Interest paid	20,935,849	27,312,291
B.	Net cash from operating activity	49,470,656	(93,964)
	Cash flow from investing activities		
	Purchase of fixed assets	(7,989,778)	(19,867,888)
	Investments	-	850,673
	Sale/ Transfer of fixed assets	(7,989,778)	(19,017,215)
	Net cash used in investing activity	(1,327,917)	4,372,256
C.	Cash flow from financing activity		
	Proceeds from loans	-	-
	Increase in Capital	-	-
	Increase in Other Equity	(1,327,917)	4,372,256
	Net cash generated in financing activity	40,152,960	(14,738,923)
	Net increase in cash and cash equivalents (A+B+C)	21,962,145	36,701,068
	Cash and cash equivalents as at 31.03.2020	62,115,106	21,962,145

Place:Hyderabad
Date:23.06.2021

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors
[Signature]
K. Krishna Kishore
Vice Chairman & Managing Director

[Signature]
M Srikanth Sasidhar
CFO

